Immunosuppression and the Risk of Post-Transplant Malignancy among Cadaveric First Kidney Transplant Recipients

American Journal of Transplantation

Volumn 4, Issue 1, 2004, Pages 87-93

  Bustami, Rami T ^a   Ojo, Akinlolu O ^a,b   Wolfe, Robert A ^b,c   Merion, Robert M ^a,d   Bennett, William M ^e   McDiarmid, Suzanne V ^f   Leichtman, Alan B ^a,b   Held, Philip J ^a   Port, Friedrich K ^a  

^a Univ Ren Res and Educ Assoc   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^f UCLA MEDICAL CENTER   (United States)

Author keywords

Antilymphocyte antibodies; Cadaveric kidney transplantation; De novo tumors; Immunosuppression; Induction therapy; PTLD; Risk factors

Indexed keywords

CYCLOSPORIN; LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CADAVER KIDNEY; CANCER RISK; CLINICAL PRACTICE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SOLID TUMOR; SURGICAL RISK;

CADAVER; CELL TRANSPLANTATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LINEAR MODELS; LOGISTIC MODELS; LYMPHOCYTES; LYMPHOPROLIFERATIVE DISORDERS; MALE; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS; TIME FACTORS; TRANSPLANTS;

EID: 0742301290     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.2003.00274.x     Document Type: Article

References (25)

1. Kew CE 2nd, Lopez-Ben R, Smith JK et al. Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation 2000; 69: 809-814.
2. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001; 27: 409-413.
3. Ondrus D, Pribylincova V, Breza J et al. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy. Int Urol Nephrol 1999; 31: 417-422.
4. Jain AB, Yee LD, Nalesnik MA et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193-1200.
5. Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996; 2: 52-59.
6. Mihalov ML, Gattuso P, Abraham K et al. Incidence of posttransplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996; 10: 248-255.
7. Barrett WL, First MR, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 1993; 72: 2186-2189.
8. National Kidney Federation. Cancer after kidney transplantation. Available at: http://www.kidney.org.uk/Medical-Info/transplant/txcancer.html. Accessed May 7, 2003.
9. Libertiny G, Watson CJ, Gray DW et al. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88: 1330-1334.
10. Angel LF, Cai TH, Sako EY, Levine SM. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Ann Transplant 2000; 5: 26-30.
11. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516.
12. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456-464.
13. Winter P, Schoeneich G, Miersch WD, Klehr HU. Tumour induction as a consequence of immunosuppression after renal transplantation. Int Urol Nephrol 1997; 29: 701-709.
14. Younes BS, McDiarmid SV, Martin MG et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94-99.
15. Jamil B, Nicholls K, Becker GJ, Walker RG. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999; 68: 1597-1603.
16. U.S. Renal Data System. USRDS 1998 Annual Data Report. Bethesda, MD: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 1998.
17. Melosky B, Karim M, Chui A et al. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression. J Am Soc Nephrol 1992; 2: S290-S294.
18. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769-772.
19. 2002 OPTN/SRTR Annual Report 1991-2001. HHS/HRSA/OSP/DOT; UNOS; URREA.
20. Dickinson DM, Ellison MD, Webb RL. SRTR Report on the State of Transplantation: data sources and structure. Am J Transplant 2003; 3: 13-28.
21. Bates WD, Gray DW, Dada MA et al. Lymphoproliferative disorders in Oxford renal transplant recipients. J Clin Pathol 2003; 56: 439-446.
22. Dharnidharka VR, Sullivan EK, Stablein DM et al. North American Pediatric Renal Transplant Cooperative Study: Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065-1068.
23. Cockfield SM. Identifying the patient at risk for posttransplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 70-78.
24. Montagnino G, Lorca E, Tarantino A et al. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transplant 1996; 10: 461-469.
25. Holmes RD, Orban-Eller K, Karrer FR et al. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002; 74: 367-372.